Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan Lumigan, Alcon Travatan Studies Suggest Superiority To Xalatan

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Post-approval presentations for the two newest entrants to the glaucoma market, Allergan’s Lumigan (bimatoprost 0.03%) and Alcon’s Travatan (travoprost 0.004%), include studies suggesting potential superiority in IOP lowering to the market leader (Pharmacia’s Xalatan) and to the first-line agent timolol.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS001422

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel